AXIM BIOTECHNOLOGIES, INC. (OTCMKTS:AXIM) Files An 8-K Regulation FD Disclosure

AXIM BIOTECHNOLOGIES, INC. (OTCMKTS:AXIM) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure

Story continues below

On January 15, 2019, Axim Biotechnologies, Inc. (“Axim”) posted an updated corporate slide presentation to its investor relations website, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is being furnished with this report. Axim also issued a press release announcing the corporate slide presentation and new corporate website, a copy of which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is being furnished with this report.

The presentation and press release will both be available in the Investor Relations section of Axim’s website at ir.aximbiotech.com.

The information set forth in this Item 7.01 is being furnished to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.

By filing this Current Report on Form 8-K and furnishing the information in this Item 7.01, Axim makes no admission as to the materiality of Item 7.01 in this report or the presentation and press release available on Axim’s website. The information contained in the presentation is summary information that is intended to be considered in the context of Axim’s filings with the Securities and Exchange Commission (the “SEC”) and other public announcements that Axim makes, by press release or otherwise, from time to time. Axim undertakes no duty or obligation to publicly update or revise the information contained in this Item, although it may do so from time to time as its management believes is appropriate or as required by applicable law. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, by updating its website or through other public disclosure.

Item 7.01 Financial Statements and Exhibits.

(d)Exhibits.

ExhibitNo.Description

99.1Corporate Slide Presentation.

99.2Press Release, dated January 15, 2019.

AXIM BIOTECHNOLOGIES, INC. Exhibit

To view the full exhibit click here

About AXIM BIOTECHNOLOGIES, INC. (OTCMKTS:AXIM)

AXIM Biotechnologies, Inc., formerly Axim International, Inc., is a biotechnology company. The Company is engaged in developing the treatment of pain, spasticity, anxiety and other medical disorders with the application of cannabinoids-based products. It is focused on research, development and production of pharmaceutical, nutriceutical and cosmetic products, as well as procurement of genetically and nano-controlled active ingredients. It is engaged in the business of research, development and production of alternative and renewable sources of energy, such as high caloric content fuels produced from industrial hemp and from the byproducts of industrial hemp after completion of the oil extraction/decarboxylation process. It is engaged in the research and development of pharmaceutical delivery systems and active pharmaceutical ingredients (API) for treatment of conditions, such as Parkinson’s disease, Alzheimer’s disease, restless leg syndrome (RLS) and Crohn’s disease.

An ad to help with our costs